Integrin v&bgr;3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis

E-ISSN： 1873-5592|4|2|123-131

ISSN： 1389-4501

Source： Current Drug Targets, Vol.4, Iss.2, 2003-02, pp. : 123-131

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

The integrin receptor v&bgr;3 has been shown to play a critical role in several distinct processes, such as angiogenesis, osteoclast-mediated bone resorption and tumor metastasis. Its expression is upregulated in newly synthesized blood vessels produced in response to a variety of tumors and purified angiogenic factors. Studies show that v&bgr;3 is a critical target downstream from perhaps all angiogenic factors. Proof-of-principle that v&bgr;3 antagonists such as monoclonal antibodies and small molecules block angiogenesis and tumor growth has been obtained in several animal models. Many endogenous inhibitors of angiogenesis such as angiostatin, endostatin and tumstatin seem to work through the v&bgr;3 receptor further emphasizing the critical role of this receptor in angiogenesis. In addition, the v&bgr;3 receptor has been clearly implicated in several pathological processes such as rheumatoid arthritis, osteoporosis, and metastasis of prostate cancer to bone. Thus v&bgr;3 may prove to be an important target for pharmacological intervention in more than one clinical setting.